Abstract:BackgroundAn ageing population and lifestyle changes have led to increased cardiovascular disease-related morbidity and mortality in China, where an estimated 230 million people have cardiovascular disease. Long-term antiplatelet therapy with aspirin and clopidogrel are used for treatment and post-stenting primary prevention of acute coronary syndrome, but the risk of bleeding complications is high. This study aimed to identify the target of the newly developed antiplatelet agent ADTM, originating from traditional Chinese herbs. We also investigated the antiplatelet and cardioprotective effects of ADTM.MethodsWe developed ADTM by conjugating danshensu and tetramethylpyrazine, which are active compounds in the herbs danshen (Salvia miltiorrhizae) and chuanxiong (Ligustium wallichii Franch), respectively. To identify the target of ADTM, we incubated its biotinylated analogue with rat blood platelet lysates, then used chemical proteomics to precipitate protein complexes. We compared the antiplatelet effect of ADTM with clopidogrel in a rat model in vivo by administrating ADTM (5–20 mg/kg) and clopidogrel (18 mg/kg) intravenously daily for 5 days, and inducing platelet aggregation by adenosine diphosphate. We also assessed the inhibitory effects of ADTM and clopidogrel on ferric chloride (FeCl3)-induced venous thrombus formation. We further assessed the cardioprotective effects of ADTM in a canine coronary artery occlusion-reperfusion model. The left anterior descending coronary artery was occluded for 20 min followed by reperfusion in five beagles (weighing about 12 kg). 15 min after occlusion, ADTM (6mg/kg) or nitroglycerin (45 μg) was administered for 3 min continuously.FindingsResults of chemical proteomics showed that ADTM targets ERp57. The inhibitory effects of ADTM on platelet aggregation were similar to clopidogrel in the rat model (mean 40% [SD 11] for ADTM [p=0·018 vs control] and 38% [9] for clopidogrel [p=0·0073 vs control; p=0·78 vs ADTM). Similarly, the inhibitory effects on FeCl3-induced venous thrombus formation were 50% (SD 10) for ADTM (p=0·0087 vs vehicle control) and 42% (6) for clopidogrel (p=0·0093 vs vehicle control; p=0·85 vs ADTM). ADTM increased mean coronary blood flow by 36% (SD 15; p=0·0165 for before vs after ADTM administration) and decreased mean arterial pressure (MAP) from 102 mm Hg (2·7) to 96 mm Hg (1·3; p=0·0031). Coronary blood flow did not differ between before and after nitroglycerin administration (p=0·49), but nitroglycerin did decrease mean arterial pressure from 102 mm Hg (1·6) to 92 mm Hg (1·5; p=0·0076). ADTM and nitroglycerin reduced the infarct size of cardiac tissue by a mean of 10% (SD 3; p=0·0217) and 8% (2; p=0·0072), respectively.InterpretationADTM is a ligand that targets ERp57 and displays antiplatelet and cardioprotective effects in animal models. ADTM represents a potential lead compound for further investigation and development of new antiplatelet drugs with reduced bleeding risk.FundingThe National Natural Science Foundation of China (NSFC-81403139) and University of Macau (MYRG2015-00161-ICMS-QRCM).

Platelet Proteomics and Tissue Metabolomics Investigation for the Mechanism of Aspirin Eugenol Ester on Preventive Thrombosis Mechanism in a Rat Thrombosis Model

Multi-Omics Approaches for Liver Reveal the Thromboprophylaxis Mechanism of Aspirin Eugenol Ester in Rat Thrombosis Model

Resveratrol Attenuates Thromboxane A2 Receptor Agonist-Induced Platelet Activation by Reducing Phospholipase C Activity.

Preventive Effect of Aspirin Eugenol Ester on Thrombosis in Κ-Carrageenan-induced Rat Tail Thrombosis Model.

Hydroxyls on the B Ring and Gallic Acyl Are Essential for Catechins to Restrain ADP-induced Thrombosis.

Theaflavin: a Natural Candidate to Restrain Thrombosis

Cellular Metabolomics Reveal the Mechanism Underlying the Anti-Atherosclerotic Effects of Aspirin Eugenol Ester on Vascular Endothelial Dysfunction

Eugenol Suppresses Platelet Activation and Mitigates Pulmonary Thromboembolism in Humans and Murine Models

Eugenol: A Potential Modulator of Human Platelet Activation and Mouse Mesenteric Vascular Thrombosis via an Innovative cPLA2-NF-κB Signaling Axis

Aspirin eugenol ester ameliorates LPS-induced inflammatory responses in RAW264.7 cells and mice

Platelet Glycoproteins Associated with Aspirin-Treatment Upon Platelet Activation

Untargeted and Targeted Metabolomics Reveal the Underlying Mechanism of Aspirin Eugenol Ester Ameliorating Rat Hyperlipidemia via Inhibiting FXR to Induce CYP7A1

The Synergistic Effect of Ginkgo Biloba Extract 50 and Aspirin Against Platelet Aggregation

Development of the Novel Antiplatelet Agent ADTM, Originating from Traditional Chinese Medicine: a Chemical Proteomic Analysis and In-Vivo Assessment of Efficacy in an Animal Model

Stachydrine Exhibits a Novel Antiplatelet Property and Ameliorates Platelet-Mediated Thrombo-Inflammation.

Metabolomics study of anti-platelet effect of Radix Paeoniae Rubra and Radix Paeoniae Alba by UPLC-MS

Inhibitory signaling of 17β-estradiol in platelet activation: the pivotal role of cyclic AMP-mediated nitric oxide synthase activation.

Metabolomics and network pharmacology reveal the mechanism of antithrombotic effect of Asperosaponin VI

The Protective Effect of Aspirin Eugenol Ester on Oxidative Stress to PC12 Cells Stimulated with H2O2 through Regulating PI3K/Akt Signal Pathway

Extract from Rostellularia procumbens (L.) Nees Inhibits Thrombosis and Platelet Aggregation by Regulating Integrin β 3 and MAPK Pathways

Design, Synthesis and Biological Evaluation of Novel Trimethylpyrazine-2-carbonyloxy-cinnamic Acids As Potent Cardiovascular Agents